[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 33 of about 33
1. Hukin J, Siffert J, Velasquez L, Zagzag D, Allen J: Leptomeningeal dissemination in children with progressive low-grade neuroepithelial tumors. Neuro Oncol; 2002 10;4(4):253-60
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leptomeningeal dissemination in children with progressive low-grade neuroepithelial tumors.
  • Our purpose is to describe the incidence and clinical features of leptomeningeal dissemination (LM) in children with progressive low-grade neuroepithelial tumor (LGN).
  • Satisfactorily followed data were obtained on 427 of the 588 patients with localized LGN at diagnosis between 1986 and 1998, 177 (42%) of whom developed progressive or recurrent disease.
  • The primary tumor sites were diencephalon (6), brainstem (3), cerebellum (2), cerebrum (1), and spinal cord (1).
  • Management included chemotherapy (2) or radiotherapy (3) or both (7); 1 patient received only radical resections of symptomatic lesions.
  • We strongly urge that for optimum treatment planning all patients with recurrent LGN be staged with an enhanced spine and brain MRI before adjuvant therapy is initiated.
  • The good survival of patients with LGN and LM reflects a more indolent disease than malignant CNS tumors with LM.
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Combined Modality Therapy. Disease Progression. Female. Humans. Infant. Magnetic Resonance Imaging. Male. Neoplasm Recurrence, Local / epidemiology. Neoplasm Recurrence, Local / therapy. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12356355.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1920666
  •  go-up   go-down


2. Clarke JL, Perez HR, Jacks LM, Panageas KS, Deangelis LM: Leptomeningeal metastases in the MRI era. Neurology; 2010 May 4;74(18):1449-54
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leptomeningeal metastases in the MRI era.
  • BACKGROUND: Diagnosis of leptomeningeal metastasis (LM) has become increasingly frequent.
  • Diagnosis was made by malignant cytology or imaging; suspicious cases treated as LM were also included.
  • The most common types of solid tumor were breast (65 patients), lung (47), gastrointestinal (11), and melanoma (9).
  • Treatment included radiation therapy in 55%, intrathecal chemotherapy in 29%, and systemic chemotherapy in 18%; 21% received supportive care alone.
  • In multivariate analysis, initial KPS and tumor type (solid vs hematopoietic) were significant predictors of survival.
  • CONCLUSIONS: Despite enhanced diagnosis with MRI, prognosis remains poor in leptomeningeal metastasis.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurology. 2005 May 10;64(9):1625-7 [15883329.001]
  • [Cites] J Neurosurg. 1997 Nov;87(5):694-9 [9347977.001]
  • [Cites] J Neurooncol. 2009 Jun;93(2):205-12 [19043775.001]
  • [Cites] J Neurooncol. 2002 May;57(3):231-9 [12125986.001]
  • [Cites] J Neurol Sci. 2004 Aug 30;223(2):167-78 [15337619.001]
  • [Cites] Arch Neurol. 1974 Feb;30(2):122-37 [4405841.001]
  • [Cites] Postgrad Med J. 1980 Mar;56(653):149-58 [7393804.001]
  • [Cites] Cancer. 1982 Feb 15;49(4):759-72 [6895713.001]
  • [Cites] Acta Cytol. 1984 Jan-Feb;28(1):29-36 [6582737.001]
  • [Cites] Neurology. 1985 Sep;35(9):1274-8 [3839573.001]
  • [Cites] Isr J Med Sci. 1988 Sep-Oct;24(9-10):611-8 [3144516.001]
  • [Cites] Hematol Oncol Clin North Am. 1990 Oct;4(5):915-36 [2262485.001]
  • [Cites] J Neurooncol. 1990 Dec;9(3):225-9 [2086737.001]
  • [Cites] Ann Neurol. 1995 Jul;38(1):51-7 [7611725.001]
  • [Cites] Arch Neurol. 1996 Jul;53(7):626-32 [8929170.001]
  • [CommentIn] Neurology. 2011 Jan 11;76(2):200; author reply 200-1 [21220726.001]
  • (PMID = 20439847.001).
  • [ISSN] 1526-632X
  • [Journal-full-title] Neurology
  • [ISO-abbreviation] Neurology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / UO1 CA-105663-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2871005
  •  go-up   go-down


3. Yang WQ, Senger D, Muzik H, Shi ZQ, Johnson D, Brasher PM, Rewcastle NB, Hamilton M, Rutka J, Wolff J, Wetmore C, Curran T, Lee PW, Forsyth PA: Reovirus prolongs survival and reduces the frequency of spinal and leptomeningeal metastases from medulloblastoma. Cancer Res; 2003 Jun 15;63(12):3162-72
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reovirus prolongs survival and reduces the frequency of spinal and leptomeningeal metastases from medulloblastoma.
  • Medulloblastoma (MB), the most common pediatric brain tumor, is a highly malignant disease with a 5-year survival rate of only 60%.
  • Tumor cells invade surrounding tissue and disseminate through cerebral spinal fluid, making treatment difficult.
  • Human reovirus type 3 exploits an activated Ras pathway in tumor cells to support productive infection as an oncolytic virus.
  • Here, we examined the ability of human reovirus to kill MB cells lines and surgical specimens in vitro and inhibit tumor growth/metastases in vivo.
  • Repeating this experiment with GFP-labeled Daoy cells and multiple i.t. administrations of reovirus, we again found prolonged survival and a dramatic reduction in spinal and leptomeningeal metastases (66.7% in control injections versus 0.0% in the live virus group).
  • These data suggest that this oncolytic virus may be a potentially effective novel therapy against human MB.
  • [MeSH-major] Biological Therapy. Cerebellar Neoplasms / therapy. Mammalian orthoreovirus 3 / physiology. Medulloblastoma / secondary. Meningeal Neoplasms / secondary. Spinal Cord Neoplasms / secondary
  • [MeSH-minor] Animals. Drug Administration Schedule. Enzyme Activation. Eukaryotic Initiation Factor-2 / antagonists & inhibitors. Female. Genes, Reporter. Genes, p53. Green Fluorescent Proteins. Humans. Injections, Spinal. Luminescent Proteins / analysis. Luminescent Proteins / genetics. Mice. Mice, Nude. Neoplasm Proteins / physiology. Proto-Oncogene Proteins p21(ras) / physiology. Signal Transduction. Transcription, Genetic. Tumor Cells, Cultured. Virus Replication. Xenograft Model Antitumor Assays. eIF-2 Kinase / antagonists & inhibitors. eIF-2 Kinase / physiology

  • Genetic Alliance. consumer health - Medulloblastoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12810644.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA21765
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Eukaryotic Initiation Factor-2; 0 / Luminescent Proteins; 0 / Neoplasm Proteins; 147336-22-9 / Green Fluorescent Proteins; EC 2.7.11.1 / eIF-2 Kinase; EC 3.6.5.2 / HRAS protein, human; EC 3.6.5.2 / Proto-Oncogene Proteins p21(ras)
  •  go-up   go-down


Advertisement
4. Kawataki T, Sato E, Sato T, Kinouchi H: Anaplastic ganglioglioma with malignant features in both neuronal and glial components--case report. Neurol Med Chir (Tokyo); 2010;50(3):228-31
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic ganglioglioma with malignant features in both neuronal and glial components--case report.
  • A 34-year-old man presented with a case of anaplastic ganglioglioma with malignant features in both neuronal and glial components manifesting as seizure episodes over 11 months.
  • The tumor was subtotally removed, followed by irradiation and chemotherapy.
  • Two months later, the tumor recurred with more pleomorphic appearance and higher cellularity with increased nestin expression level.
  • Cytological examination found dissemination to the leptomeningeal space.
  • The expression of nestin may suggest that the origin or malignant transformation in anaplastic gangliogliomas is related to the undifferentiated neural stem cells.
  • [MeSH-major] Brain Neoplasms / pathology. Ganglioglioma / pathology. Intermediate Filament Proteins / metabolism. Neoplasm Proteins / metabolism. Nerve Tissue Proteins / metabolism. Neuroglia / pathology. Neurons / pathology
  • [MeSH-minor] Adult. Anaplasia. Fatal Outcome. Humans. Male. Neoplasm Recurrence, Local. Nestin. Seizures / etiology. Seizures / pathology. Temporal Lobe / cytology. Temporal Lobe / metabolism. Temporal Lobe / pathology

  • Genetic Alliance. consumer health - Ganglioglioma.
  • Genetic Alliance. consumer health - Anaplastic Ganglioglioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20339274.001).
  • [ISSN] 1349-8029
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Intermediate Filament Proteins; 0 / NES protein, human; 0 / Neoplasm Proteins; 0 / Nerve Tissue Proteins; 0 / Nestin
  •  go-up   go-down


5. Rogers LR, Remer SE, Tejwani S: Durable response of breast cancer leptomeningeal metastasis to capecitabine monotherapy. Neuro Oncol; 2004 Jan;6(1):63-4
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Durable response of breast cancer leptomeningeal metastasis to capecitabine monotherapy.
  • We report a durable (12-month) response to capecitabine monotherapy, shown clinically, by MRI, and by cerebrospinal fluid analysis, in a patient with leptomeningeal metastasis from breast cancer.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Brain Neoplasms / secondary. Breast Neoplasms / drug therapy. Deoxycytidine / analogs & derivatives. Deoxycytidine / therapeutic use. Meningeal Neoplasms / drug therapy. Meningeal Neoplasms / secondary. Orbital Neoplasms / secondary
  • [MeSH-minor] Adult. Capecitabine. Female. Fluorouracil / analogs & derivatives. Humans. Treatment Outcome

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2001 Jan;84(2):157-63 [11161370.001]
  • [Cites] Am J Clin Oncol. 2001 Aug;24(4):421-4 [11474279.001]
  • [Cites] Acta Neurol Scand. 1986 Sep;74(3):240-4 [2947416.001]
  • [Cites] Cancer Treat Rev. 1999 Apr;25(2):103-19 [10395835.001]
  • [Cites] Curr Opin Oncol. 1992 Jun;4(3):533-9 [1379833.001]
  • [Cites] J Neurooncol. 1998 Jun-Jul;38(2-3):151-7 [9696366.001]
  • [Cites] Cancer. 1991 Mar 15;67(6):1685-95 [2001559.001]
  • (PMID = 14769142.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC1871963
  •  go-up   go-down


6. Debnam JM, Schellingerhout D, Kumar AJ, Ketonen L, Shah K, Hamberg LM, Hunter GJ: Multidetector CT-Guided Lumbar Puncture in Patients with Cancer. Interv Neuroradiol; 2009 Mar 31;15(1):61-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multidetector CT-Guided Lumbar Puncture in Patients with Cancer.
  • SUMMARY: Lumbar puncture can be performed for therapeutic purposes, to instill intrathecal chemotherapy for leptomeningeal cancer treatment or prophylaxis.
  • The purpose of this article is to describe the technique and to evaluate outcomes of MDCT-guided lumber puncture for diagnostic and therapeutic purposes in patients with cancer.
  • We conclude that MDCT-guided lumbar puncture is an effective and safe guiding modality for thecal sac access in patients with cancer, particularly where other methods of intrathecal access have failed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Dis Child. 1986 Aug;140(8):737-8 [3728388.001]
  • [Cites] J Clin Oncol. 2002 Jun 15;20(12):2783-8 [12065554.001]
  • [Cites] Cancer Invest. 2006 Aug-Sep;24(5):528-34 [16939963.001]
  • [Cites] Arch Intern Med. 2002 Sep 9;162(16):1904-5 [12196091.001]
  • [Cites] J Nucl Med. 1971 Aug;12(8):555-7 [5093427.001]
  • [Cites] JAMA. 2002 Oct 23-30;288(16):2001-7 [12387652.001]
  • [Cites] Can J Neurol Sci. 2002 May;29(2):147-53 [12035835.001]
  • [Cites] Anesthesiology. 2006 Aug;105(2):381-93 [16871073.001]
  • [Cites] Ann Hematol. 2001 Feb;80(2):113-5 [11261321.001]
  • [Cites] Anesth Analg. 2004 Feb;98(2):524-6, table of contents [14742399.001]
  • [Cites] Pediatr Emerg Care. 1986 Sep;2(3):180-2 [3537983.001]
  • [Cites] N Engl J Med. 1981 Oct 29;305(18):1079-81 [6974306.001]
  • [Cites] Surg Neurol. 2005 Jan;63(1):52-5; discussion 55 [15639526.001]
  • [Cites] J Emerg Med. 1994 Sep-Oct;12(5):597-601 [7989684.001]
  • [Cites] J Neurooncol. 2002 May;57(3):231-9 [12125986.001]
  • [Cites] Arch Dis Child. 1987 Sep;62(9):873-5 [3674939.001]
  • [Cites] Pediatr Emerg Care. 2001 Jun;17(3):184-8 [11437143.001]
  • [Cites] Ann Intern Med. 1986 Jun;104(6):840-8 [3518565.001]
  • [Cites] Emerg Med (Fremantle). 2001 Sep;13(3):351-8 [11554868.001]
  • [Cites] JAMA. 1981 Apr 10;245(14):1456-9 [7206149.001]
  • [Cites] AJR Am J Roentgenol. 2003 Jul;181(1):231-4 [12818865.001]
  • [Cites] Neurol Sci. 2001 Oct;22(5):385-9 [11917976.001]
  • [Cites] J Pediatr. 1985 Aug;107(2):249-51 [4020548.001]
  • [Cites] Blood. 2000 Nov 15;96(10):3381-4 [11071631.001]
  • [Cites] Ann Hematol. 2001;80 Suppl 3:B113-7 [11757691.001]
  • [Cites] Pediatrics. 2003 Sep;112(3 Pt 1):e174-6 [12949308.001]
  • [Cites] J Infect Dis. 1990 Jul;162(1):251-4 [2355199.001]
  • [Cites] Am J Med. 1987 Jun;82(6):1175-81 [3605134.001]
  • (PMID = 20465930.001).
  • [ISSN] 1591-0199
  • [Journal-full-title] Interventional neuroradiology : journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences
  • [ISO-abbreviation] Interv Neuroradiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3306150
  •  go-up   go-down


7. Beauchesne P: Intrathecal chemotherapy for treatment of leptomeningeal dissemination of metastatic tumours. Lancet Oncol; 2010 Sep;11(9):871-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intrathecal chemotherapy for treatment of leptomeningeal dissemination of metastatic tumours.
  • Neoplastic meningitis consists of diffuse involvement of the leptomeninges by infiltrating cancer cells, and can be caused by systemic or primary CNS tumours, such as solid cancers or lymphoproliferative malignant disease.
  • Because most patients with neoplastic meningitis have diffuse systemic disease, treatment is typically palliative.
  • However, more aggressive treatments are available to low-risk patients, which could increase survival.
  • Intrathecal chemotherapy is currently the main treatment for patients with neoplastic meningitis, but optimum anticancer chemotherapy is being studied.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Meningeal Carcinomatosis / drug therapy. Meningeal Carcinomatosis / secondary. Neoplasm Metastasis / drug therapy
  • [MeSH-minor] Humans. Injections, Spinal. Meningitis / etiology. Neoplasms / complications. Neoplasms / drug therapy. Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20598636.001).
  • [ISSN] 1474-5488
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 75
  •  go-up   go-down


8. Mehta M, Bradley K: Radiation therapy for leptomeningeal cancer. Cancer Treat Res; 2005;125:147-58
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiation therapy for leptomeningeal cancer.
  • Radiotherapy has multiple roles in the treatment of leptomeningeal cancer.
  • While it is uncommon for patients to experience regression of neurologic deficits due to leptomeningeal cancer, focal radiotherapy often provides significant palliation of pain, increased intracranial pressure and other focal symptoms.
  • Focal radiotherapy may also be used to eliminate blockages of cerebrospinal fluid (CSF) and allow for safe administration of intrathecal chemotherapy.
  • Craniospinal irradiation (CSI) is most often used as prophylaxis for patients at high risk of leptomeningeal tumor dissemination, but may result in symptom palliation and prolonged disease control for patients with active leptomeningeal tumor.

  • MedlinePlus Health Information. consumer health - Pain.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16211888.001).
  • [ISSN] 0927-3042
  • [Journal-full-title] Cancer treatment and research
  • [ISO-abbreviation] Cancer Treat. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 26
  •  go-up   go-down


9. Clayton J, Vloeberghs M, Jaspan T, Walker D, MacArthur D, Grundy R: Intrathecal chemotherapy delivered by a lumbar-thecal catheter in metastatic medulloblastoma: a case illustration. Acta Neurochir (Wien); 2008 Jul;150(7):709-12
Hazardous Substances Data Bank. Topotecan .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intrathecal chemotherapy delivered by a lumbar-thecal catheter in metastatic medulloblastoma: a case illustration.
  • BACKGROUND: Medulloblastoma is the most common malignant brain tumour in children.
  • Intrathecal chemotherapy, is an ideal but currently underused method of directly targeting residual tumour within the area of resection and the leptomeningeal disease commonly associated with this tumour.
  • CONCLUSION: This method represents a simple, safe and effective method of delivering an even and widespread distribution of drug within the cerebrospinal fluid (CSF) of the neuroaxis.
  • With new agents being identified and others in the early stages of development, intrathecal chemotherapy may emerge as an important therapeutic option to consider when faced with such challenging cases.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Cerebellar Neoplasms / drug therapy. Cerebellar Neoplasms / pathology. Cerebral Ventricle Neoplasms / drug therapy. Medulloblastoma / drug therapy. Medulloblastoma / secondary
  • [MeSH-minor] Arachnoid / pathology. Catheterization. Child. Female. Humans. Injections, Spinal / methods. Lumbosacral Region. Magnetic Resonance Imaging. Neoplasm Invasiveness. Pia Mater / pathology. Radiography, Thoracic. Topotecan / administration & dosage. Topotecan / therapeutic use

  • Genetic Alliance. consumer health - Medulloblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18401539.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 7M7YKX2N15 / Topotecan
  •  go-up   go-down


10. Kochi M, Itoyama Y, Shiraishi S, Kitamura I, Marubayashi T, Ushio Y: Successful treatment of intracranial nongerminomatous malignant germ cell tumors by administering neoadjuvant chemotherapy and radiotherapy before excision of residual tumors. J Neurosurg; 2003 Jul;99(1):106-14
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of intracranial nongerminomatous malignant germ cell tumors by administering neoadjuvant chemotherapy and radiotherapy before excision of residual tumors.
  • OBJECT: The goal of this study was to confirm the effectiveness of our novel treatment strategy, neoadjuvant therapy (NAT) consisting of combined chemo- and radiotherapy, which are performed before complete excision of residual tumor in patients with intracranial nongerminomatous malignant germ cell tumors (NGMGCTs).
  • METHODS: The authors treated 11 consecutive patients with NGMGCTs by applying NAT consisting of combined platinum-based chemotherapy and radiotherapy, followed by complete excision of residual tumors.
  • The pretreatment diagnosis, based on tumor markers with or without biopsy, was yolk sac tumor in five patients, embryonal carcinoma in one patient, immature teratoma in one patient, and mixed germ cell tumor containing malignant tumor components in four patients.
  • In one patient a leptomeningeal tumor recurred and he died of the disease 21 months after diagnosis.
  • CONCLUSIONS: Neoadjuvant therapy, consisting of combined chemo- and radiotherapy, followed by complete excision of residual tumors is highly effective in patients with intracranial NGMGCTs.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms. Carcinoma. Endodermal Sinus Tumor. Germinoma. Neoadjuvant Therapy / methods. Neoplasms, Germ Cell and Embryonal
  • [MeSH-minor] Adolescent. Adult. Biomarkers, Tumor. Biopsy. Child. Combined Modality Therapy. Disease Progression. Drug Administration Schedule. Female. Humans. Magnetic Resonance Imaging. Male. Neoplasm, Residual / pathology. Neoplasm, Residual / surgery. Postoperative Care. Quality of Life. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12854751.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


11. Clatot F, Philippin-Lauridant G, Ouvrier MJ, Nakry T, Laberge-Le-Couteulx S, Guillemet C, Veyret C, Blot E: Clinical improvement and survival in breast cancer leptomeningeal metastasis correlate with the cytologic response to intrathecal chemotherapy. J Neurooncol; 2009 Dec;95(3):421-426
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical improvement and survival in breast cancer leptomeningeal metastasis correlate with the cytologic response to intrathecal chemotherapy.
  • Leptomeningeal meningitis occurs in approximately 5% of metastatic breast cancers, and there is no standard treatment for this complication.
  • We retrospectively analyzed the clinical data and cerebrospinal fluid of 24 patients treated with high-dose intrathecal methotrexate for breast cancer leptomeningeal meningitis (BLM).
  • Cytologic response (CSF cytology without neoplastic cells after treatment) was observed in 11 patients (46%) and related to survival (P = 0.005).
  • Cytologic response could be helpful in the management of intrathecal chemotherapy in patients with BLM.
  • [MeSH-minor] Adult. Aged. Cerebrospinal Fluid / cytology. Female. Humans. Injections, Spinal. Middle Aged. Neoplasm Staging. Predictive Value of Tests. Prognosis. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer. 2004 Dec;40(18):2726-33 [15571954.001]
  • [Cites] Cancer. 1996 Apr 1;77(7):1315-23 [8608509.001]
  • [Cites] J Clin Oncol. 1993 Mar;11(3):561-9 [8445432.001]
  • [Cites] J Neurooncol. 2005 Oct;75(1):85-99 [16215819.001]
  • [Cites] J Neurooncol. 1997 Oct;35(1):55-64 [9266441.001]
  • [Cites] Cancer. 1991 Mar 15;67(6):1685-95 [2001559.001]
  • [Cites] Jpn J Clin Oncol. 2003 Dec;33(12):608-12 [14769837.001]
  • [Cites] Anticancer Res. 2002 Sep-Oct;22(5):3057-9 [12530042.001]
  • [Cites] J Neurooncol. 2007 Aug;84(1):57-62 [17310266.001]
  • [Cites] Clin Cancer Res. 1999 Nov;5(11):3394-402 [10589750.001]
  • [Cites] South Med J. 1995 Mar;88(3):357-62 [7886538.001]
  • [Cites] Neuro Oncol. 2008 Apr;10(2):208-15 [18316473.001]
  • [Cites] Oncologist. 2008 Sep;13(9):967-77 [18776058.001]
  • [Cites] Ann Oncol. 1996 Oct;7(8):773-86 [8922190.001]
  • (PMID = 19557501.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


12. Ortega-Martínez M, Cabezudo-Artero JM, Fernández-Portales I, Pimentel JJ, Gómez de Tejada R: Diffuse leptomeningeal seeding from benign choroid plexus papilloma. Acta Neurochir (Wien); 2007 Dec;149(12):1229-36; discussion 1236-7
Genetic Alliance. consumer health - Choroid Plexus Papilloma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffuse leptomeningeal seeding from benign choroid plexus papilloma.
  • Although they are histologically benign, local recurrences may occasionally occur, but leptomeningeal dissemination is exceptional.
  • We report an unusual example of a fourth ventricle choroid plexus papilloma with diffuse leptomeningeal seeding.
  • Neither the initial tumour nor the recurrence showed malignant histological features.
  • Treatment with systemic and intrathecal chemotherapy was ineffective in this patient.
  • We review the literature concerning leptomeningeal dissemination of benign choroid plexus papillomas.
  • [MeSH-major] Cerebral Ventricle Neoplasms / surgery. Fourth Ventricle / surgery. Meningeal Neoplasms / secondary. Neoplasm Seeding. Papilloma, Choroid Plexus / surgery
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Biopsy. Disease Progression. Fatal Outcome. Female. Humans. Ki-67 Antigen / analysis. Laminectomy. Magnetic Resonance Imaging. Meninges / pathology. Reoperation. S100 Proteins / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17924056.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / S100 Proteins
  •  go-up   go-down


13. Norris LS, Snodgrass S, Miller DC, Wisoff J, Garvin J, Rorke LB, Finlay JL: Recurrent central nervous system medulloepithelioma: response and outcome following marrow-ablative chemotherapy with stem cell rescue. J Pediatr Hematol Oncol; 2005 May;27(5):264-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent central nervous system medulloepithelioma: response and outcome following marrow-ablative chemotherapy with stem cell rescue.
  • Medulloepithelioma is a rare primitive neuroectodermal tumor of the central nervous system usually developing in childhood, displaying highly malignant behavior, with early progression or recurrence.
  • The purpose of this study was to evaluate the efficacy of high-dose, marrow-ablative chemotherapy with autologous hemopoietic stem cell rescue in the treatment of recurrent central nervous system medulloepithelioma.
  • Three young children with recurrent central nervous system medulloepithelioma received high-dose marrow-ablative chemotherapy with thiotepa and etoposide either alone (one patient) or with the addition of carboplatin (two patients).
  • One child with residual radiographic tumor at the time of treatment could be evaluated for response and showed complete resolution of leptomeningeal disease after receiving marrow-ablative chemotherapy.
  • Two children developed tumor recurrence at 2.0 and 5.5 months after receiving marrow-ablative chemotherapy.
  • The third child continues free of tumor beyond 12 years from treatment.
  • The authors' experience with marrow-ablative chemotherapy and autologous hemopoietic stem cell rescue suggests that this treatment strategy might be beneficially incorporated into the initial treatment approach for young children with medulloepithelioma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma / therapy. Central Nervous System Neoplasms / therapy. Neoplasm Recurrence, Local. Stem Cell Transplantation
  • [MeSH-minor] Child, Preschool. Combined Modality Therapy. Female. Humans. Magnetic Resonance Imaging. Male. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15891561.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Jaeckle KA: Improving the outcome of patients with leptomeningeal cancer: new clinical trials and experimental therapies. Cancer Treat Res; 2005;125:181-93
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improving the outcome of patients with leptomeningeal cancer: new clinical trials and experimental therapies.
  • Current therapy for leptomeningeal metastases is predominantly palliative.
  • In an effort to improve disease control and patient outcome, new strategies are being developed to target the cerebrospinal space.
  • These include new intrathecal formulations of systemic chemotherapy as well as the development of radiolabeled immunoconjugates and antitumor antibodies.
  • Furthermore, there is debate as to the optimal strategy of drug delivery for leptomeningeal tumor.
  • [MeSH-major] Meningeal Neoplasms / drug therapy
  • [MeSH-minor] Antineoplastic Agents / administration & dosage. Antineoplastic Agents / therapeutic use. Clinical Trials as Topic / methods. Clinical Trials as Topic / trends. Humans. Injections, Spinal. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16211890.001).
  • [ISSN] 0927-3042
  • [Journal-full-title] Cancer treatment and research
  • [ISO-abbreviation] Cancer Treat. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 50
  •  go-up   go-down


15. Saito R, Kumabe T, Jokura H, Yoshimoto T: Fatal hemorrhage after radiochemotherapy for leptomeningeal dissemination of glioma: report of two cases. Surg Neurol; 2002 Jan;57(1):46-8
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fatal hemorrhage after radiochemotherapy for leptomeningeal dissemination of glioma: report of two cases.
  • BACKGROUND: Dissemination of malignant gliomas is often observed, but the treatment of choice for leptomeningeal dissemination has not been established.
  • CASE DESCRIPTIONS: A 55-year-old man suffered fatal hemorrhage 1 day after whole brain irradiation (2 Gy) along with intravenous administration of 150 mg of nitrosourea (ACNU) for leptomeningeal dissemination of glioblastoma.
  • A 14-year-old boy suffered hemorrhage after intrathecal administration of 10 mg of methotrexate for recurrence of leptomeningeal dissemination of anaplastic astrocytoma 4 months after local brain irradiation and ACNU administration, and died 19 days later.
  • CONCLUSION: Massive fatal hemorrhage is an unusual but possible acute complication after radiochemotherapy for leptomeningeal dissemination of gliomas.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Astrocytoma / drug therapy. Astrocytoma / radiotherapy. Glioblastoma / drug therapy. Glioblastoma / radiotherapy. Meningeal Neoplasms / drug therapy. Meningeal Neoplasms / radiotherapy. Methotrexate / adverse effects. Radiotherapy / adverse effects. Subarachnoid Hemorrhage / etiology
  • [MeSH-minor] Adolescent. Combined Modality Therapy. Fatal Outcome. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local. Time Factors. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11834277.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


16. Oechsle K, Lange-Brock V, Kruell A, Bokemeyer C, de Wit M: Prognostic factors and treatment options in patients with leptomeningeal metastases of different primary tumors: a retrospective analysis. J Cancer Res Clin Oncol; 2010 Nov;136(11):1729-35

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors and treatment options in patients with leptomeningeal metastases of different primary tumors: a retrospective analysis.
  • PURPOSE: Leptomeningeal metastases (LM) are associated with very poor prognosis and data on outcome are limited.
  • We evaluated prognostic factors and treatment options in patients (pts) with LM of different malignancies in a single center experience.
  • METHODS: Single center data on characteristics, treatment and outcome of 135 consecutive pts (73 solid tumors and 62 hematologic malignancies) with LM between 1989 and 2005 were retrospectively analyzed.
  • RESULTS: Treatment consisted of systemic chemotherapy (SC) plus intrathecal chemotherapy (ITC) in 28%, ITC alone in 22%, radiotherapy (RT) plus ITC in 12% and other modalities (SC, RT, SC + RT) in 7%.
  • Thirteen percent of pts received supportive care only (4% not evaluable on treatment).
  • Univariate analysis revealed age >50, interval between diagnosis of primary tumor and LM ≤12 months, lung cancer and malignant melanoma, and Karnofsky performance status ≤70 as significant negative predictors for overall survival.
  • CONCLUSIONS: In patients with LM an age >50, performance status ≤70%, interval between diagnosis of primary tumor and LM ≤12 months, primary tumor (lung cancer, malignant melanoma) and lack of cytologic response present negative prognostic factors.
  • Systemic chemotherapy is significantly associated with longer survival time than local treatment modalities.
  • [MeSH-major] Meningeal Carcinomatosis / pathology. Neoplasm Metastasis / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Combined Modality Therapy. Female. Hematologic Neoplasms / drug therapy. Hematologic Neoplasms / mortality. Hematologic Neoplasms / pathology. Humans. Lung Neoplasms / drug therapy. Lung Neoplasms / mortality. Lung Neoplasms / pathology. Lung Neoplasms / radiotherapy. Male. Melanoma / drug therapy. Melanoma / mortality. Melanoma / pathology. Melanoma / radiotherapy. Middle Aged. Neoplasms / drug therapy. Neoplasms / mortality. Neoplasms / pathology. Prognosis. Proportional Hazards Models. Retrospective Studies. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurol Sci. 2004 Aug 30;223(2):167-78 [15337619.001]
  • [Cites] Eur J Cancer. 2004 Dec;40(18):2726-33 [15571954.001]
  • [Cites] Curr Opin Oncol. 2006 Nov;18(6):637-43 [16988587.001]
  • [Cites] Cancer. 1996 Apr 1;77(7):1315-23 [8608509.001]
  • [Cites] J Clin Oncol. 1993 Mar;11(3):561-9 [8445432.001]
  • [Cites] Cancer Invest. 2005;23(2):145-54 [15813508.001]
  • [Cites] Neurology. 1994 Aug;44(8):1463-9 [8058150.001]
  • [Cites] J Neurooncol. 2006 Jul;78(3):255-60 [16344918.001]
  • [Cites] Expert Opin Pharmacother. 2005 Jun;6(7):1115-25 [15957966.001]
  • [Cites] Cancer. 2007 Dec 15;110(12):2640-7 [17960791.001]
  • [Cites] J Neurooncol. 1997 Oct;35(1):55-64 [9266441.001]
  • [Cites] Jpn J Clin Oncol. 2003 Dec;33(12):608-12 [14769837.001]
  • [Cites] J Clin Oncol. 1998 Apr;16(4):1561-7 [9552066.001]
  • [Cites] J Neurooncol. 2007 Aug;84(1):107-17 [17332946.001]
  • [Cites] Neuro Oncol. 2008 Apr;10(2):199-207 [18287337.001]
  • [Cites] J Clin Oncol. 1999 Oct;17(10):3110-6 [10506606.001]
  • [Cites] J Neurooncol. 2007 Aug;84(1):57-62 [17310266.001]
  • [Cites] Cancer. 1998 May 1;82(9):1756-63 [9576299.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3605-13 [15908671.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Mar 1;37(4):745-51 [9128946.001]
  • (PMID = 20204406.001).
  • [ISSN] 1432-1335
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


17. Martin-Blondel G, Rousseau A, Boch AL, Cacoub P, Sène D: Primary pineal melanoma with leptomeningeal spreading: case report and review of the literature. Clin Neuropathol; 2009 Sep-Oct;28(5):387-94
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary pineal melanoma with leptomeningeal spreading: case report and review of the literature.
  • Magnetic resonance imaging revealed a pineal mass hyperintense on T1-weighted and isointense on T2-weighted sequences with diffuse leptomeningeal involvement and intense homogeneous contrast enhancement after gadolinium administration.
  • A frontal leptomeningeal and cortical biopsy was performed.
  • Histological examination showed a malignant melanocytic tumor cell proliferation expressing Melan-A, but not HMB-45 or S100 protein.
  • Even if we have no proof that the tumor actually arose in the pineal gland, based on the radiological and histological findings, and on the unremarkable dermatologic and ophthalmologic examinations, a primary pineal melanoma with leptomeningeal dissemination was diagnosed.
  • The patient received temozolomide-based chemotherapy followed by whole brain irradiation.
  • The patient died 52 weeks after disease onset and 13 weeks after treatment initiation.
  • The diagnosis is provided by pathological examination of tumor specimens obtained at surgical resection or at leptomeningeal biopsy.
  • However, immunochemistry using anti-Melan-A, -S100 protein and/or -HMB45 antibodies on cerebrospinal fluid and leptomeningeal samples may be helpful in diagnosing such a disease.
  • The best therapeutic management is yet to be defined.
  • [MeSH-minor] Adult. Antigens, Neoplasm / metabolism. Brain / pathology. Brain / radiography. Brain / radionuclide imaging. Diagnosis, Differential. Fatal Outcome. Humans. MART-1 Antigen. Magnetic Resonance Imaging. Male. Melanoma-Specific Antigens. Neoplasm Proteins / metabolism. Prognosis. S100 Proteins / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19788056.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / MART-1 Antigen; 0 / MLANA protein, human; 0 / Melanoma-Specific Antigens; 0 / Neoplasm Proteins; 0 / S100 Proteins
  • [Number-of-references] 20
  •  go-up   go-down


18. Takahashi M, Yamada R, Tabei Y, Nakamura O, Shinoura N: Navigation-guided Ommaya reservoir placement: implications for the treatment of leptomeningeal metastases. Minim Invasive Neurosurg; 2007 Dec;50(6):340-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Navigation-guided Ommaya reservoir placement: implications for the treatment of leptomeningeal metastases.
  • Ommaya reservoirs are commonly used in the diagnosis and management of leptomeningeal metastases (LM) from malignant tumors.
  • Computed tomographic (CT) scans were routinely obtained just after completion of the procedure.
  • Patients diagnosed with LM received subsequent treatment.
  • Using the real-time "Guidance View", the surgeon was able to verify the catheter position continuously during the procedure.
  • [MeSH-major] Catheters, Indwelling / standards. Infusion Pumps, Implantable / standards. Meningeal Neoplasms / drug therapy. Meningeal Neoplasms / secondary. Neuronavigation / methods. Neurosurgical Procedures / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Agents / administration & dosage. Brain / anatomy & histology. Brain / radiography. Brain / surgery. Female. Humans. Hydrocephalus / etiology. Hydrocephalus / physiopathology. Injections, Intraventricular / instrumentation. Injections, Intraventricular / methods. Intracranial Hemorrhages / etiology. Lateral Ventricles / anatomy & histology. Lateral Ventricles / radiography. Lateral Ventricles / surgery. Male. Middle Aged. Neoplasm Metastasis / drug therapy. Postoperative Complications / etiology. Postoperative Complications / physiopathology. Postoperative Complications / prevention & control. Surgical Wound Infection / prevention & control. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18210356.001).
  • [ISSN] 0946-7211
  • [Journal-full-title] Minimally invasive neurosurgery : MIN
  • [ISO-abbreviation] Minim Invasive Neurosurg
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


19. Toledano Delgado R, Garcia N, Riva-Amarante E, Rodríguez Pascual J, García Leal R, Sendra Tello J: [Spinal leptomeningeal metastasis from cerebral glioblastoma: case report]. Neurologia; 2006 Sep;21(7):378-81
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Spinal leptomeningeal metastasis from cerebral glioblastoma: case report].
  • INTRODUCTION: Glioblastoma multiforme (GBM) is the most common primary malignant tumor of the central nervous system.
  • Spinal leptomeningeal metastasis (SLM) due to a GBM are well documented at autopsy in patients previously diagnosed of GBM, however, systemic dissemination with symptomatic leptomeningeal metastasis is quite rare.
  • Most of the time it is diagnosed late and misdiagnosis is a common problem.
  • CASE REPORT: We present a case of a 65-year-old man with a right temporal GBM treated by surgical resection, radiotherapy and chemotherapy, who is readmitted 10 months later as he developed an ataxic gait.
  • Awareness of this complication might facilitate more rapid diagnosis and treatment.
  • [MeSH-minor] Aged. Humans. Lumbar Vertebrae / pathology. Male. Neoplasm Invasiveness

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16977559.001).
  • [ISSN] 0213-4853
  • [Journal-full-title] Neurología (Barcelona, Spain)
  • [ISO-abbreviation] Neurologia
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


20. Alexiou GA, Moschovi M, Stefanaki K, Prodromou C, Sfakianos G, Prodromou N: Malignant progression of a pleomorphic xanthoastrocytoma in a child. Neuropediatrics; 2010 Aug;41(2):69-71
Hazardous Substances Data Bank. GADOLINIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant progression of a pleomorphic xanthoastrocytoma in a child.
  • Pleomorphic xanthoastrocytoma (PXA) is a recently recognized rare cerebral neoplasm that predominantly affects young patients.
  • 1 year later follow-up magnetic resonance imaging (MRI) revealed tumor relapse.
  • An MRI of the spine was also performed and demonstrated leptomeningeal dissemination.
  • Histology revealed that the presence of a malignant PXA with anaplastic features.
  • The patient received radiotherapy and 9 months later on follow-up MRI a new tumor recurrence was noted.
  • A third craniotomy was performed and the tumor removed.
  • The patient was referred to the oncology department and received chemotherapy with temozolamide.
  • 8 months later the patient was stable without tumor recurrence.
  • [MeSH-minor] Child, Preschool. Disease Progression. Gadolinium. Humans. Magnetic Resonance Imaging. Male. Tomography, X-Ray Computed / methods

  • Genetic Alliance. consumer health - Pleomorphic xanthoastrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Georg Thieme Verlag KG Stuttgart.New York.
  • (PMID = 20799153.001).
  • [ISSN] 1439-1899
  • [Journal-full-title] Neuropediatrics
  • [ISO-abbreviation] Neuropediatrics
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] AU0V1LM3JT / Gadolinium
  •  go-up   go-down


21. Minchom A, Chan S, Melia W, Shah R: An unusual case of pancreatic cancer with leptomeningeal infiltration. J Gastrointest Cancer; 2010 Jun;41(2):107-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An unusual case of pancreatic cancer with leptomeningeal infiltration.
  • INTRODUCTION: Pancreatic cancer is a common malignancy and often presents at an advanced stage.
  • We aim to describe an unusual case of leptomeningeal involvement from pancreatic cancer.
  • MRI study of the brain and spinal cord showed widespread leptomeningeal enhancement.
  • He started on a weekly regimen of intrathecal combination chemotherapy of hydrocortisone 50 mg, methotrexate 12.5 mg and cytarabine 50 mg.
  • His clinical condition continued to deteriorate, cytotoxic therapy was withdrawn after 2 weeks and he died the following month.
  • DISCUSSION: This case represents the unusual presentation of advanced leptomeningeal carcinomatosis in a locally early stage pancreatic adenocarcinoma.
  • [MeSH-minor] Anti-Inflammatory Agents / administration & dosage. Antimetabolites, Antineoplastic / administration & dosage. Cytarabine / administration & dosage. Drug Therapy, Combination. Fatal Outcome. Humans. Hydrocortisone / administration & dosage. Male. Methotrexate / administration & dosage. Middle Aged

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurology. 2006 Mar 14;66(5):783; author reply 783 [16534138.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Ann Oncol. 2004;15 Suppl 4:iv285-91 [15477323.001]
  • [Cites] Neurochirurgia (Stuttg). 1980 Jan;23(1):13-7 [7352044.001]
  • [Cites] Cancer Treat Rev. 1999 Apr;25(2):103-19 [10395835.001]
  • [Cites] Gan To Kagaku Ryoho. 2008 Dec;35(13):2413-6 [19098414.001]
  • [Cites] Acta Neurol (Napoli). 1975 Jul-Aug;30(4):359-67 [1229842.001]
  • [Cites] Neurosurgery. 2000 Jul;47(1):49-54; discussion 54-5 [10917346.001]
  • [Cites] Cancer Treat Res. 2005;125:147-58 [16211888.001]
  • [Cites] Ann Oncol. 2008 Jul;19(7):1224-30 [18381371.001]
  • [Cites] Ann Oncol. 1996 Oct;7(8):773-86 [8922190.001]
  • (PMID = 20069465.001).
  • [ISSN] 1941-6636
  • [Journal-full-title] Journal of gastrointestinal cancer
  • [ISO-abbreviation] J Gastrointest Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Antimetabolites, Antineoplastic; 04079A1RDZ / Cytarabine; WI4X0X7BPJ / Hydrocortisone; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


22. Friedman JA, Lynch JJ, Buckner JC, Scheithauer BW, Raffel C: Management of malignant pineal germ cell tumors with residual mature teratoma. Neurosurgery; 2001 Mar;48(3):518-22; discussion 522-3
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of malignant pineal germ cell tumors with residual mature teratoma.
  • OBJECTIVE: The treatment of intracranial mixed germ cell tumors presents a unique challenge, since eradication of malignant tumor by radiation and/or chemotherapy may spare the benign tumor component.
  • We reviewed our surgical experience with residual malignant pineal germ cell tumors after neoadjuvant therapy.
  • METHODS: Between 1987 and 1997, 16 patients with malignant intracranial germ cell tumors were treated at the Mayo Clinic with a protocol of neoadjuvant chemotherapy and radiation therapy.
  • After the diagnosis was confirmed by histopathological examination, all patients were treated with four cycles of etoposide and cisplatin as well as external beam radiation therapy (range, 3030-5940 cGy).
  • Six patients had an incomplete response to therapy, as demonstrated by observation of residual tumor on magnetic resonance imaging scans.
  • Initial pathology in these six patients was germinoma in four and combinations of yolk sac tumor, embryonal carcinoma, malignant teratoma, and germinoma in two.
  • Two patients had synchronous pineal and suprasellar tumors, with leptomeningeal dissemination.
  • Tumor markers were elevated in four of the six patients at presentation.
  • CONCLUSION: Residual pineal tumor occurring after treatment of malignant intracranial germ cell tumor with neoadjuvant therapy is likely to be mature teratoma.
  • [MeSH-minor] Adolescent. Adult. Algorithms. Child. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Neoplasm, Residual


23. Rudnicka H, Niwińska A, Murawska M: Breast cancer leptomeningeal metastasis--the role of multimodality treatment. J Neurooncol; 2007 Aug;84(1):57-62
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast cancer leptomeningeal metastasis--the role of multimodality treatment.
  • AIM: The aim of the study was to assess the efficacy of multimodality treatment of patients with Leptomeningeal metastasis (LM) and to establish which method of treatment has the greatest positive impact on survival.
  • MATERIAL AND METHODS: Clinical material included 67 consecutive breast cancer patients with LM treated at the Cancer Center in Warsaw between the years 2000 and 2005.
  • Intrathecal chemotherapy was given to 57 pts (85%), intravenous chemotherapy to 41 pts (61%), whole brain radiotherapy to 33 pts (49%) and radiotherapy to the spinal leptomeninges to 10 (15%).
  • For 27 pts (40%) three methods of treatment were used.
  • Univariate and multivariate analyses were used to evaluate the impact of the particular method of treatment on survival and to assess the efficacy of combined modalities.
  • Univariate analysis showed positive impact of systemic intravenous chemotherapy (P = 0.0009), intrathecal chemotherapy (P = 0.008) and whole brain radiotherapy (P = 0.004) on survival.
  • The results of Cox multivariate analysis have shown systemic chemotherapy (P < 0.001) and intrathecal chemotherapy (P = 0.001) to be significant.
  • CONCLUSIONS: Intravenous chemotherapy and, independently, intrathecal chemotherapy improve survival in breast cancer patients with LM.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Breast Neoplasms / pathology. Carcinoma / secondary. Meningeal Neoplasms / secondary. Radiotherapy / methods
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy / methods. Dexamethasone / administration & dosage. Disease-Free Survival. Humans. Infusions, Intravenous. Injections, Spinal. Kaplan-Meier Estimate. Methotrexate / administration & dosage. Middle Aged. Statistics, Nonparametric. Treatment Outcome

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer. 2004 Dec;40(18):2726-33 [15571954.001]
  • [Cites] J Neurooncol. 1998 Jun-Jul;38(2-3):193-8 [9696371.001]
  • [Cites] J Clin Oncol. 1987 Oct;5(10):1655-62 [3309199.001]
  • [Cites] Cancer. 1996 Apr 1;77(7):1315-23 [8608509.001]
  • [Cites] J Clin Oncol. 1993 Mar;11(3):561-9 [8445432.001]
  • [Cites] Cancer. 1994 Dec 15;74(12):3135-41 [7982179.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1988 Oct;51(10):1277-83 [3225584.001]
  • [Cites] J Clin Oncol. 1986 Jan;4(1):68-73 [3079822.001]
  • [Cites] Neurology. 1983 Dec;33(12):1565-72 [6685829.001]
  • [Cites] Neurology. 1994 Aug;44(8):1463-9 [8058150.001]
  • [Cites] Cancer. 1982 Feb 15;49(4):759-72 [6895713.001]
  • [Cites] Cancer. 1994 Apr 1;73(7):1892-4 [8137217.001]
  • [Cites] Arch Neurol. 1994 May;51(5):457-61 [8179494.001]
  • [Cites] Cancer Treat Rev. 1999 Apr;25(2):103-19 [10395835.001]
  • [Cites] Cancer. 1991 Mar 15;67(6):1685-95 [2001559.001]
  • [Cites] Cancer Res. 1977 Apr;37(4):1232-7 [844048.001]
  • [Cites] J Clin Oncol. 1998 Apr;16(4):1561-7 [9552066.001]
  • [Cites] Lung Cancer. 1993 Dec;10(3-4):247-9 [8075970.001]
  • [Cites] Cancer. 1981 Oct 15;48(8):1724-37 [6793225.001]
  • [Cites] Cancer. 1998 May 1;82(9):1756-63 [9576299.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3605-13 [15908671.001]
  • [Cites] Cancer. 1982 Jul 15;50(2):219-22 [6177395.001]
  • [Cites] Oncology (Williston Park). 1991 May;5(5):107-16; discussion 123, 127 [1831994.001]
  • [Cites] Cancer Res. 1989 May 1;49(9):2502-5 [2468411.001]
  • [Cites] Ann Oncol. 1996 Oct;7(8):773-86 [8922190.001]
  • (PMID = 17310266.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 7S5I7G3JQL / Dexamethasone; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


24. Friedman HS: Temozolomide in early stages of newly diagnosed malignant glioma and neoplastic meningitis. Semin Oncol; 2000 Jun;27(3 Suppl 6):35-40
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Temozolomide in early stages of newly diagnosed malignant glioma and neoplastic meningitis.
  • Traditional approaches to leptomeningeal metastases, such as radiation and intrathecal chemotherapy, have limited success and a high degree of toxicity.
  • Temozolomide offers a number of potential therapeutic advantages in this disorder, including activity against a wide spectrum of human cancers that produce neoplastic meningitis and penetration of the blood-brain barrier.
  • Recently, intrathecal temozolomide has been shown to increase median survival in athymic rats bearing subarachnoid human malignant glioma xenografts.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Astrocytoma / drug therapy. Brain Neoplasms / drug therapy. Dacarbazine / analogs & derivatives. Glioma / drug therapy. Meningitis / drug therapy
  • [MeSH-minor] Animals. Clinical Trials as Topic. Humans. Mice. Mice, Nude. Neoplasm Staging. Quality of Life. Transplantation, Heterologous

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Meningitis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10866348.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  • [Number-of-references] 20
  •  go-up   go-down


25. van der Wal EJ, Azzarelli B, Edwards-Brown M: Malignant transformation of a chiasmatic pilocytic astrocytoma in a patient with diencephalic syndrome. Pediatr Radiol; 2003 Mar;33(3):207-10
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant transformation of a chiasmatic pilocytic astrocytoma in a patient with diencephalic syndrome.
  • We report leptomeningeal spread of a chiasmatic pilocytic astrocytoma in a child presenting with diencephalic syndrome.
  • He was treated with chemotherapy and radiation.
  • The tumor recurred with transformation into a high-grade astrocytoma.
  • Radiation therapy may have played a role in transformation of the tumor, but more research is needed to further clarify the biological behavior of this tumor.
  • [MeSH-major] Astrocytoma / secondary. Cell Transformation, Neoplastic / pathology. Diencephalon / physiopathology. Meningeal Neoplasms / secondary. Neoplasm Invasiveness / pathology. Optic Chiasm / pathology. Optic Nerve Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Biopsy, Needle. Child, Preschool. Combined Modality Therapy. Cranial Irradiation. Follow-Up Studies. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Male. Risk Assessment. Syndrome

  • Genetic Alliance. consumer health - Diencephalic Syndrome.
  • Genetic Alliance. consumer health - Pilocytic astrocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12612823.001).
  • [ISSN] 0301-0449
  • [Journal-full-title] Pediatric radiology
  • [ISO-abbreviation] Pediatr Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


26. Kim HJ, Kim YJ, Seo MD, Yi HG, Lee SH, Lee SM, Kim DW, Yang SC, Lee CT, Lee JS, Kim YW, Heo DS: Patterns of palliative procedures and clinical outcomes in patients with advanced non-small cell lung cancer. Lung Cancer; 2009 Aug;65(2):242-6
MedlinePlus Health Information. consumer health - Palliative Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patterns of palliative procedures and clinical outcomes in patients with advanced non-small cell lung cancer.
  • BACKGROUND: Despite recent progress in palliative chemotherapy for advanced non-small cell lung cancer (NSCLC), the prognosis is still poor.
  • Aside from multiple lines of chemotherapy, many patients need palliative procedures due to disease-related events.
  • METHODS: We evaluated 162 patients who were diagnosed with stage IIIB (with malignant effusion) or IV NSCLC at Seoul National University Hospital in 2005.
  • Forty-nine patients (30%) needed a palliative procedure at the time of diagnosis, and 59 patients (36%) required palliative procedure later during the course of their treatment.
  • The events requiring palliative procedures were thoracic events (malignant effusion or severe pneumonia requiring intensive care unit care not related to treatment) in 32 (30%), CNS events (brain metastasis or leptomeningeal metastasis) in 37 (34%), skeletal events (bone metastasis requiring radiation, spinal cord compression, hypercalcemia) in 29 (27%), and other events in 10 (9%).
  • The patients who had events at the time of diagnosis showed comparable overall survival to the patients without events at the time of diagnosis (14.6 months vs. 13.3 months, p=0.65).
  • The patients with later events during their course of treatment had a short median survival after the event requiring palliative procedures (median 2.7 months, 95% CI 2.19-3.21).
  • CONCLUSION: A considerable proportion of patients with advanced NSCLC receive palliative procedures apart from chemotherapy.
  • These interventions should be taken into consideration for comprehensive cancer care and timely cooperation with palliative care team.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / complications. Carcinoma, Non-Small-Cell Lung / therapy. Lung Neoplasms / complications. Lung Neoplasms / therapy. Palliative Care / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Staging

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19147252.001).
  • [ISSN] 1872-8332
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  •  go-up   go-down


27. Lin C, Turner S, Gurney H, Peduto A: Increased detections of leptomeningeal presentations in men with hormone refractory prostate cancer: an effect of improved systemic therapy? J Med Imaging Radiat Oncol; 2008 Aug;52(4):376-81
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased detections of leptomeningeal presentations in men with hormone refractory prostate cancer: an effect of improved systemic therapy?
  • Metastases from prostate cancer occur largely in bone through a haematogenous route.
  • Metastatic spread of prostate cancer to the leptomeninges was rarely seen in the past.
  • However, there has been a recent increase in presentations of leptomeningeal spread from prostate cancer in our institutions.
  • Between 2004 and 2006, four patients were diagnosed with metastatic prostate cancer with leptomeningeal metastases in our centres.
  • All four patients had hormone refractory prostate cancer and had previously had chemotherapy.
  • The median survival of these patients was approximately 15 months from the time of hormone refractoriness.
  • The prognosis of leptomeningeal metastasis secondary to metastatic prostate cancer is poor, ranging from 2 to 7 months as seen in our series.
  • New cases of leptomeningeal metastases seen in our series are hypothesized to be secondary to the use of effective modern systemic treatments.
  • A parallel might be drawn with the increased rate of central nervous system metastases in breast cancer since the introduction of effective cytotoxic treatments and more recently targeted therapies.
  • We suggest the clinicians to be aware of the potential change of natural history and pattern of progression in metastatic prostate cancer.
  • [MeSH-minor] Aged. Hormones / therapeutic use. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18811763.001).
  • [ISSN] 1754-9485
  • [Journal-full-title] Journal of medical imaging and radiation oncology
  • [ISO-abbreviation] J Med Imaging Radiat Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Hormones
  •  go-up   go-down


28. Koeller KK, Rushing EJ: From the archives of the AFIP: medulloblastoma: a comprehensive review with radiologic-pathologic correlation. Radiographics; 2003 Nov-Dec;23(6):1613-37
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Medulloblastoma is the most common pediatric central nervous system malignancy and the most common primary tumor of the posterior fossa in children.
  • This highly malignant neoplasm occurs more frequently in males and usually before 10 years of age.
  • Clinical symptoms and signs are generally brief, typically less than 3 months in duration, and reflect the strong predilection of this tumor to arise within the cerebellum, most often in the vermis.
  • Surgical resection, radiation therapy, and chemotherapy have substantially lowered the mortality associated with this tumor, with 5-year survival rates now commonly well above 50%.
  • Still, both dissemination at the time of diagnosis and recurrence remain obstacles in achieving a cure.
  • The tumor has characteristic hyperattenuation on unenhanced computed tomographic scans that reflects the high nuclear-cytoplasmic ratio seen at histologic analysis.
  • The tumor typically appears heterogeneous on images, findings that are related to cyst formation, hemorrhage, and calcification and that are even more pronounced with magnetic resonance (MR) imaging.
  • Evidence of leptomeningeal metastatic spread is present in 33% of all cases at the time of diagnosis and is well evaluated with contrast-enhanced MR imaging of the brain and the spine.
  • With continued research, treatment of these common neoplasms should improve, perhaps even achieving a cure in the future.
  • [MeSH-major] Cerebellar Neoplasms / radiography. Magnetic Resonance Imaging. Medulloblastoma / radiography. Tomography, X-Ray Computed
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Female. Humans. Infant. Male. Meninges / pathology. Middle Aged. Neoplasm Invasiveness. Prognosis. Survival Rate

  • Genetic Alliance. consumer health - Medulloblastoma.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14615567.001).
  • [ISSN] 1527-1323
  • [Journal-full-title] Radiographics : a review publication of the Radiological Society of North America, Inc
  • [ISO-abbreviation] Radiographics
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 102
  •  go-up   go-down


29. Chamberlain MC: Anticancer therapies and CNS relapse: overcoming blood-brain and blood-cerebrospinal fluid barrier impermeability. Expert Rev Neurother; 2010 Apr;10(4):547-61
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anticancer therapies and CNS relapse: overcoming blood-brain and blood-cerebrospinal fluid barrier impermeability.
  • Prolonged survival with targeted therapies has sometimes come at the expense of an increased risk of CNS relapse; because many of these agents poorly penetrate the BBB, malignant cells may remain viable within the CNS.
  • The ability of anticancer drugs to penetrate the BBB is a major consideration in the treatment of CNS parenchymal metastases.
  • Optimal chemotherapy approaches for treating CNS metastases remain unclear due to a lack of evidence-based recommendations.
  • Recent hypothesis-generating studies evaluating intra-cerebrospinal fluid administration of targeted agents indicate that these drugs may be effective in treating leptomeningeal disease and are associated with a low incidence of drug-related adverse events.
  • Newer strategies for treating cerebrospinal fluid metastases may co-opt endogenous systems of the BBB, such as those involved in receptor-mediated transcytosis or classic carrier-mediated transporter systems to facilitate drug delivery across the BBB.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Blood-Brain Barrier / physiology. Central Nervous System Neoplasms / drug therapy
  • [MeSH-minor] Animals. Combined Modality Therapy. Humans. Injections, Spinal. Neoplasm Metastasis / drug therapy. Neurosurgical Procedures. Radiotherapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20367207.001).
  • [ISSN] 1744-8360
  • [Journal-full-title] Expert review of neurotherapeutics
  • [ISO-abbreviation] Expert Rev Neurother
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 125
  •  go-up   go-down


30. Fisher PG, Kadan-Lottick NS, Korones DN: Intrathecal thiotepa: reappraisal of an established therapy. J Pediatr Hematol Oncol; 2002 May;24(4):274-8
Hazardous Substances Data Bank. THIO-TEPA .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intrathecal thiotepa: reappraisal of an established therapy.
  • PURPOSE: Intrathecal thiotepa is recommended as a treatment of leptomeningeal metastases (LM) in children, although published data to support this approach are limited.
  • RESULTS: Fifteen children with LM evidenced by malignant cells in the cerebrospinal fluid (mean age 7.3 years; five medulloblastoma, one anaplastic astrocytoma, one glioblastoma, one retinoblastoma, one neuroblastoma, two rhabdomyosarcoma, one non-Hodgkin lymphoma, two acute lymphoblastic leukemia, and one acute myelogenous leukemia) were treated with intrathecal thiotepa at 5 to 11.5 mg/m2 per dose for two to seven doses.
  • Five children received concomitant craniospinal irradiation; 12 received simultaneous systemic or other intrathecal chemotherapy, or both.
  • Four children experienced clearance of malignant cells from the spinal fluid, but this response was sustained in only two.
  • All four children with cytologic response received concurrent radiotherapy, chemotherapy, or both.
  • CONCLUSIONS: The unfavorable outcomes observed suggest that intrathecal thiotepa adds little to combination therapy for pediatric LM.
  • [MeSH-major] Antineoplastic Agents, Alkylating / administration & dosage. Meningeal Neoplasms / drug therapy. Thiotepa / administration & dosage
  • [MeSH-minor] Adolescent. Cerebrospinal Fluid / cytology. Child. Child, Preschool. Cohort Studies. Combined Modality Therapy. Disease-Free Survival. Female. Glioma / drug therapy. Humans. Injections, Spinal. Lymphoma, Non-Hodgkin / drug therapy. Magnetic Resonance Imaging. Male. Neoplasm Recurrence, Local / diagnosis. Neoplasm Staging. Neurologic Examination. Radiotherapy Dosage. Survival Rate. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11972095.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / K12 NSO 1692-05
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 905Z5W3GKH / Thiotepa
  •  go-up   go-down


31. Liauw SL, Byer JE, Yachnis AT, Amdur RJ, Mendenhall WM: Radiotherapy after subtotally resected or recurrent ganglioglioma. Int J Radiat Oncol Biol Phys; 2007 Jan 1;67(1):244-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The role of postoperative radiation therapy (RT) is undefined.
  • Five patients received adjuvant RT after STR at a median time of 6 weeks after surgery.
  • Three patients received salvage RT at a median time of 17 months after surgery.
  • The median dose of RT was 54 Gy.
  • Recurrences were controlled with further surgery (n = 2), chemotherapy (n = 1), or re-irradiation (n = 1) (median follow-up, 9 years after salvage therapy).
  • All 3 patients who were treated with salvage RT had recurrences in the treated area alone (n = 2) or in the treated area with leptomeningeal spread (n = 1).
  • Salvage RT for recurrence is probably less effective for long-term control; however, patients who recur may still be candidates for effective salvage therapies in the absence of malignant transformation.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Ganglioglioma / radiotherapy. Neoplasm Recurrence, Local / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Combined Modality Therapy / methods. Female. Humans. Male. Neoplasm, Residual. Radiotherapy Dosage. Radiotherapy, Adjuvant. Salvage Therapy

  • Genetic Alliance. consumer health - Ganglioglioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17045420.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Yomo S, Tada T, Hirayama S, Tachibana N, Otani M, Tanaka Y, Hongo K: A case report and review of the literature. J Neurooncol; 2007 Jan;81(2):209-16

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary diffuse leptomeningeal gliomatosis (PDLG) is a rare central nervous system neoplasm in which gliomatous tissue is diffusely identified in the subarachnoid space with no evidence of a primary intraparenchymal tumor.
  • Examinations of cerebrospinal fluid (CSF) did not show malignant cells but increased protein and pleocytosis.
  • Magnetic resonance (MR) imaging demonstrated diffuse leptomeningeal enhancement without any source of intraparenchymal lesion.
  • A biopsy disclosed wide spreading of anaplastic glial cells within the leptomeninges.
  • He died 3 months later because of disease progression despite both radiotherapy and chemotherapy.
  • Reviewing previous cases of PDLG instructs that this entity is rare, resembles meningitis in clinical pictures, usually occurs in a relatively younger population and has more progressive clinical course than the ordinary form of malignant gliomas.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Rev Neurol. 1997 Sep;25(145):1419-21 [9377304.001]
  • [Cites] Surg Neurol. 1998 Oct;50(4):356-62; discussion 362 [9817460.001]
  • [Cites] Clin Neuropathol. 1987 Jul-Aug;6(4):164-8 [3652562.001]
  • [Cites] Pathology. 1999 Feb;31(1):59-63 [10212927.001]
  • [Cites] Neurosurgery. 1986 Mar;18(3):363-6 [3703199.001]
  • [Cites] J Forensic Sci. 2001 Mar;46(2):392-5 [11305449.001]
  • [Cites] AJNR Am J Neuroradiol. 1995 May;16(5):1018-20 [7639122.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2001 Feb;70(2):256-8 [11160482.001]
  • [Cites] Arch Pathol Lab Med. 2000 May;124(5):759-61 [10782164.001]
  • [Cites] J Neurosurg. 1992 Aug;77(2):302-6 [1625019.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2001 Jan;70(1):120-2 [11118261.001]
  • [Cites] Acta Neurochir (Wien). 1995;132(1-3):154-9 [7754854.001]
  • [Cites] Neurosurgery. 1995 Jan;36(1):166-8; discussion 169 [7708153.001]
  • [Cites] Acta Neurochir (Wien). 1990;102(3-4):145-8 [2336982.001]
  • [Cites] Neurol Sci. 2005 Jun;26(2):129-34 [15995830.001]
  • [Cites] Can J Neurol Sci. 1985 Aug;12 (3):278-81 [4052890.001]
  • [Cites] Am J Clin Oncol. 1999 Jun;22(3):243-6 [10362329.001]
  • [Cites] Pediatr Radiol. 1998 Aug;28(8):580-2 [9716625.001]
  • [Cites] Yonsei Med J. 2000 Aug;41(4):517-21 [10992815.001]
  • [Cites] J Neuropathol Exp Neurol. 1951 Jan;10(1):16-29 [14804124.001]
  • [Cites] Neurosurgery. 2003 Feb;52(2):324-29; discussion 330 [12535360.001]
  • [Cites] Acta Neuropathol. 2005 Sep;110(3):306-11 [16003541.001]
  • [Cites] J Neurooncol. 1998 Apr;37(2):161-7 [9524095.001]
  • [Cites] Childs Nerv Syst. 2003 Jun;19(5-6):298-304 [12761643.001]
  • [Cites] Acta Neurochir (Wien). 1996;138(4):480-1 [8738401.001]
  • [Cites] Clin Neuropathol. 2000 May-Jun;19(3):126-30 [14606585.001]
  • [Cites] Clin Neurol Neurosurg. 2000 Dec;102(4):223-226 [11154809.001]
  • [Cites] J Comput Assist Tomogr. 1993 Mar-Apr;17(2):317-20 [8454762.001]
  • [Cites] J Neuroimaging. 1996 Oct;6(4):250-4 [8903081.001]
  • [Cites] J Neurooncol. 1993 Mar;15(3):275-83 [8360714.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2000 Sep;69(3):385-8 [10945815.001]
  • [Cites] J Neurooncol. 2005 Jul;73(3):261-4 [15980977.001]
  • [Cites] J Neurooncol. 1993 Jan;15(1):45-9 [8455062.001]
  • [Cites] Zentralbl Pathol. 1991;137(6):523-30 [1805932.001]
  • [Cites] Acta Neuropathol. 1990;80(3):338-41 [2399813.001]
  • [Cites] Rev Neurol (Paris). 1994;150(3):232-5 [7863170.001]
  • [Cites] Rev Neurol (Paris). 1994 Oct;150(10):700-3 [7792477.001]
  • [Cites] Eur J Radiol. 2001 Jan;37(1):5-7 [11274832.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1994 Apr;57(4):471-3 [8163998.001]
  • [Cites] J Neurosurg. 1986 Jun;64(6):968-73 [3701447.001]
  • [Cites] J Neurooncol. 2001 May;53(1):21-6 [11678426.001]
  • [Cites] Childs Nerv Syst. 2005 Jun;21(6):477-81 [15378329.001]
  • [Cites] J Neurosurg. 1995 Oct;83(4):724-8 [7674024.001]
  • [Cites] Childs Nerv Syst. 2003 Apr;19(4):197-203 [12682758.001]
  • [Cites] Br J Neurosurg. 2001 Feb;15(1):62-6 [11303666.001]
  • [Cites] J Neurosurg. 1985 Aug;63(2):283-7 [4020450.001]
  • (PMID = 17031563.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Zarovnaya EL, Pallatroni HF, Hug EB, Ball PA, Cromwell LD, Pipas JM, Fadul CE, Meyer LP, Park JP, Biegel JA, Perry A, Rhodes CH: Atypical teratoid/rhabdoid tumor of the spine in an adult: case report and review of the literature. J Neurooncol; 2007 Aug;84(1):49-55
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical teratoid/rhabdoid tumor of the spine in an adult: case report and review of the literature.
  • Atypical teratoid/rhabdoid tumors (AT/RTs) are rare, malignant brain tumors which occur almost exclusively in infants and young children.
  • There have been only 17 cases of AT/RT in adults reported in the medical literature and the rarity of this tumor makes the diagnosis in adults difficult.
  • Subsequently, immunohistochemical studies revealed the absence of INI1 gene expression in the malignant cells, supporting the diagnosis of AT/RT.
  • The patient underwent three additional surgical procedures for recurrent disease throughout the neuraxis secondary to leptomeningeal spread of the tumor.
  • Despite aggressive surgical resection, adjuvant chemotherapy and radiation therapy, the patient succumbed to the disease two and a half years after her initial presentation.
  • To our knowledge, this is the first case of a spinal atypical teratoid/rhabdoid tumor in an adult fully documented with molecular, immunohistochemical, cytogenetic and autopsy findings.
  • [MeSH-major] Chromosomal Proteins, Non-Histone / genetics. Chromosomes, Human, Pair 22 / genetics. DNA-Binding Proteins / genetics. Neoplasm Recurrence, Local / pathology. Rhabdoid Tumor / pathology. Spinal Cord Neoplasms / pathology. Teratoma / pathology. Transcription Factors / genetics

  • Genetic Alliance. consumer health - Rhabdoid tumor.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurooncol. 2001 Mar;52(1):49-56 [11451202.001]
  • [Cites] J Neurooncol. 2003 Jan;61(2):121-6 [12622450.001]
  • [Cites] Nature. 1998 Jul 9;394(6689):203-6 [9671307.001]
  • [Cites] Genes Dev. 2005 Mar 15;19(6):665-70 [15769941.001]
  • [Cites] Mod Pathol. 2005 Jul;18(7):951-8 [15761491.001]
  • [Cites] J Neurooncol. 1995;24(1):21-8 [8523069.001]
  • [Cites] Cancer Res. 2005 May 15;65(10 ):4012-9 [15899790.001]
  • [Cites] Can J Neurol Sci. 1996 Nov;23(4):257-63 [8951203.001]
  • [Cites] Neuroradiology. 2000 May;42(5):363-7 [10872158.001]
  • [Cites] Pathol Int. 1999 Dec;49(12):1114-8 [10632935.001]
  • [Cites] Acta Neuropathol. 1992;83(4):445-8 [1575023.001]
  • [Cites] J Neurooncol. 2005 Sep;74(3):311-9 [16132523.001]
  • [Cites] J Pediatr Hematol Oncol. 2002 Jun-Jul;24(5):337-42 [12142780.001]
  • [Cites] Med Pediatr Oncol. 1997 Mar;28(3):223-7 [9024522.001]
  • [Cites] Brain Pathol. 2005 Jan;15(1):23-8 [15779233.001]
  • [Cites] Mol Cell Biol. 2006 Apr;26(7):2661-74 [16537910.001]
  • [Cites] Neurochirurgie. 1999 Sep;45(3):237-42 [10567965.001]
  • [Cites] Nat Rev Cancer. 2004 Feb;4(2):133-42 [14964309.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1993;422(1):81-5 [7679853.001]
  • [Cites] J Neurosurg. 1996 Jul;85(1):56-65 [8683283.001]
  • [Cites] Mod Pathol. 2006 May;19(5):717-25 [16528370.001]
  • [Cites] Acta Neurochir (Wien). 2004 Sep;146(9):1033-8; discussion 1038 [15340816.001]
  • [Cites] J Neurooncol. 2005 Mar;72(1):77-84 [15803379.001]
  • [Cites] Am J Surg Pathol. 2004 May;28(5):644-50 [15105654.001]
  • [Cites] Am J Surg Pathol. 2004 Nov;28(11):1485-91 [15489652.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Mar 15;64(4):1038-43 [16406394.001]
  • [Cites] Hum Pathol. 2001 Feb;32(2):156-62 [11230702.001]
  • [Cites] Neuropathology. 2006 Feb;26(1):57-61 [16521480.001]
  • [Cites] J Clin Neurosci. 2003 May;10 (3):325-8 [12763338.001]
  • [Cites] Cancer Res. 1999 Jan 1;59(1):74-9 [9892189.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 6;102(49):17745-50 [16301525.001]
  • [Cites] Am J Surg Pathol. 1998 Sep;22(9):1083-92 [9737241.001]
  • (PMID = 17377740.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA46274
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chromosomal Proteins, Non-Histone; 0 / DNA-Binding Proteins; 0 / SMARCB1 Protein; 0 / SMARCB1 protein, human; 0 / Transcription Factors
  • [Number-of-references] 34
  •  go-up   go-down






Advertisement